Physicians and patient advocates are sounding the alarm after the NIH abruptly withdrew a grant renewal application for the ...

The FDA has approved the popular drug Dupixent (generic name, dupilumab) for adults and kids 12 and up with chronic ...

Blood eosinophil count and fractional exhaled nitric oxide significantly enhance prognostic assessment of asthma attack risk.

The IL-5 inhibitor is already available under the Fasenra brand name for maintenance use in severe eosinophilic asthma, but a new study conducted by researchers at King's College London (KCL ...

The FDA approves SNY and REGN's Dupixent for treating chronic spontaneous urticaria, marking the seventh approved indication of the drug.

Sanofi and Regeneron's Dupixent (dupilumab) has been approved by the FDA for the treatment of chronic spontaneous urticaria ...

Sanofi and Regeneron's Dupixent (dupilumab) has gained approval from the FDA for chronic spontaneous urticaria (CSU) ...

Celldex’s cash runway extends into 2027, but potential delays or hurdles could necessitate earlier fundraising, exerting ...

CEGIR, which is part of the Rare Diseases Clinical Research Network, includes more than a dozen clinical sites across the U.S. and studies chronic immune system disorders in which eosinophils ...

Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch and ...

The US Food and Drug Administration (FDA) has approved dupilumab (Dupixent) for the treatment of chronic spontaneous ...